Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMonpat Chamnanphonen_US
dc.contributor.authorNatchaya Vanwongen_US
dc.contributor.authorSantirhat Prommasen_US
dc.contributor.authorNapatrupron Koomdeeen_US
dc.contributor.authorRattanaporn Sukprasongen_US
dc.contributor.authorJiratha Rachanakulen_US
dc.contributor.authorNutthan Nuntharadthanaphongen_US
dc.contributor.authorYaowaluck Hongkaewen_US
dc.contributor.authorShobana Johnen_US
dc.contributor.authorNattawat Ngamsamuten_US
dc.contributor.authorNopphadol Nuntamoolen_US
dc.contributor.authorPenkhae Limsilaen_US
dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.otherRamathibodi Hospitalen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherBumrungrad International Hospitalen_US
dc.contributor.otherFaculty of Medicine Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherPayap Universityen_US
dc.contributor.otherFaculty of Medicine, Srinakharinwirot Universityen_US
dc.identifier.citationResearch in Autism Spectrum Disorders. Vol.96, (2022)en_US
dc.description.abstractBackground: Risperidone causes hyperprolactinemia by blocking D2 receptors on lactotrophs anterior pituitary, which prevents prolactin secretion inhibition. Risperidone is converted to 9-hydroxyrisperidone by the CYP2D6 enzyme. Polymorphisms in CYP2D6 may affect serum prolactin and could be a predictor of hyperprolactinemia. The goal of this study was to see if there was an association between CYP2D6 variants, risperidone dose, clinical data and serum prolactin levels in Thai children and adolescents with autism spectrum disorder (ASD). Method: In 107 Thai ASD patients on risperidone, allele-specific primer extension and multiplex PCR platforms were used to genotype the CYP2D6 gene. The chemiluminescence immunoassay (CLIA) technique was used to measure fasting serum prolactin levels. Results: The median serum prolactin level was 16.25 ng/mL (IQR; 10.43-22.18), and patients with CYP2D6*1/*5 (6.54%) had substantially lower prolactin levels than those with CYP2D6*1/*1 [median; 11.2 ng/mL (IQR; 3.95-21.10) vs. 21.3 (IQR; 14.43-32.18), p=0.032]. CYP2D6*1/*10, *10/*10, and *10/*41 produced less prolactin than *1/*1 (wild type). Furthermore, gender and risperidone dose were associated with significantly different prolactin levels with p-value 0.02 and 0.006, respectively. Multivariate analysis showed a significant association of serum prolactin level with body mass index and risperidone dose (p<0.05). Conclusions: Our study showed that CYP2D6 carriers of absent and decreased functional alleles had lower serum prolactin levels in Thai ASD patients treated with risperidone treatment; this is important to clinicians, indicating that they should consider about CYP2D6 genotyping before beginning risperidone in ASD patients. CYP2D6 genotypes might be a predictor for levels of prolactin in clinical treatment.en_US
dc.rightsMahidol Universityen_US
dc.titleRisperidone plasma concentrations are associated with hyperprolactinemia in autism spectrum disorder children: The impact of CYP2D6 polymorphismsen_US
Appears in Collections:Scopus 2022

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.